Torrent Pharma, Inc. v. Priority Healthcare Distribution, Inc.

CourtSuperior Court of Delaware
DecidedAugust 11, 2022
DocketN18C-05-094 CEB
StatusPublished

This text of Torrent Pharma, Inc. v. Priority Healthcare Distribution, Inc. (Torrent Pharma, Inc. v. Priority Healthcare Distribution, Inc.) is published on Counsel Stack Legal Research, covering Superior Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Torrent Pharma, Inc. v. Priority Healthcare Distribution, Inc., (Del. Ct. App. 2022).

Opinion

IN THE SUPERIOR COURT OF THE STATE OF DELAWARE

TORRENT PHARMA, INC., ) QBE UNDERWRITERS LTD., ) LIBERTY CORPORATE CAPITAL ) LTD., HAMILTON MANAGEMENT ) AGENCY LTD., RIVERSTONE ) MANAGING AGENCY LTD., BRIT ) SYNDICATES LTD., and ARGO ) MANAGING AGENCY LTD., ) C.A. No. N18C-05-094 CEB ) Plaintiffs, ) ) v. ) ) PRIORITY HEALTHCARE ) DISTRIBUTION, INC., d/b/a ) CURASCRIPT SD SPECIALTY ) DISTRIBUTION, and DENALI OHIO ) SOUTHPARK INDUSTRIAL LLC, ) ) Defendants. )

Submitted: June 10, 2022 Decided: August 11, 2022

Upon Consideration of Plaintiffs’ Motion for Summary Judgment, GRANTED IN PART and DENIED IN PART.

Upon Consideration of Defendant Priority Healthcare Distribution, Inc.’s Motion for Summary Judgment Against Plaintiffs, GRANTED IN PART and DENIED IN PART. Upon Consideration of Defendant Priority Healthcare Distribution, Inc.’s Motion for Summary Judgment Against Defendant Denali Ohio Southpark Industrial LLC, DENIED.

Upon Consideration of Defendant Priority Healthcare Distribution, Inc.’s Motion in Limine, DENIED.

Upon Consideration of Defendant Denali Ohio Southpark Industrial LLC’s Motion for Summary Judgment On the Issue of Causation, GRANTED IN PART and DENIED IN PART.

Upon Consideration of Defendant Denali Ohio Southpark Industrial LLC’s Motion for Summary Judgment On the Issue of Damages, DENIED.

MEMORANDUM OPINION

Michael B. McCauley, Esquire, PALMER BIEZUP & HENDERSON LLP, Wilmington, Delaware; Kevin G. O’Donovan, Esquire, PALMER BIEZUP & HENDERSON LLP, Philadelphia, Pennsylvania. Attorneys for Plaintiffs.

Elizabeth A. Sloan, Esquire, and Brittany M. Giusini, Esquire, BALLARD SPAHR LLP, Wilmington, Delaware; Matthew D. Knepper, Esquire, and Tanya M. Maerz, Esquire, HUSCH BLACKWELL LLP, St. Louis, Missouri. Attorneys for Defendant Priority Healthcare Distribution, Inc.

Sarah B. Cole, Esquire, MARSHALL DENNEHEY WARNER COLEMAN & GOGGIN, P.C., Wilmington, Delaware. Attorney for Defendant Denali Ohio Southpark Industrial LLC.

BUTLER, R.J.

2 Plaintiff Torrent Pharma, Inc. is an India-based pharmaceutical manufacturer

that entered a product distribution contract with Defendant Priority Healthcare

Distribution, Inc. (“CuraScript”). CuraScript agreed to manage Torrent’s

prescription drug products at a warehouse in Ohio (the “Warehouse”). CuraScript

leased the Warehouse from Defendant Denali Ohio Southpark Industrial LLC. This

litigation concerns the fallout from a leaking Warehouse pipe.

A few years ago, one of the Warehouse’s overhead sprinklers leaked water

onto 19 pallets of Torrent’s products. The leaks allegedly caused over $200,000 in

damage. Torrent and its insurers (collectively, “Underwriters”) have brought this

tort and contract action against the Defendants to recover their losses. The

Defendants, in turn, have asserted indemnification crossclaims for full coverage of

any award the Plaintiffs receive.

The parties now move for summary judgment.1 After culling a herd of issues,

the Court concludes that the Defendants are entitled to summary judgment as to the

Plaintiffs’ tort and third-party beneficiary claims and the Plaintiffs are entitled to

summary judgment as to CuraScript’s contractual liability. No party is entitled to

summary judgment as to the Plaintiffs’ damages. And neither Defendant is entitled

1 CuraScript also has moved in limine. The motion is based on the same arguments CuraScript makes in support of summary judgment. Accordingly, it is resolved— and denied—consistent with this decision. See infra Analysis § C.

3 to summary judgment as to its indemnification crossclaim. The parties’ motions are

granted and denied accordingly.

BACKGROUND2

A. The Agreements

The parties’ arrangements are expressed through two separate agreements.

Torrent and CuraScript executed a services contract (the “Logistics Agreement”)3

that operated at the Warehouse. CuraScript rented the Warehouse under a lease (the

“Lease”)4 that CuraScript’s corporate predecessor entered with the Warehouse’s

previous owner. Denali assumed the Lease when it acquired the Warehouse. Denali

is not a party to the Logistics Agreement and Torrent is not a party to the Lease.

Each agreement contains several terms that govern the issues in this case.

1. The Logistics Agreement

Under the Logistics Agreement, CuraScript agreed to “store, handle, and

transport” Torrent’s products.5 CuraScript’s duties are measured by three provisions

set out in the Logistics Agreement. The Logistics Agreement required CuraScript

to render its services consistent with (i) a dozen “Key Performance Indicators”

2 The Court draws the relevant facts from the exhibits attached to the parties’ motions. The Court has construed the record in the light most favorable to each non- movant. See infra Standard of Review. 3 Ex. A to D.I. 101 (Third-Party Logistics Agreement) [hereinafter “LA”]. 4 Ex. 1 to D.I. 97 (Lease Agreement) [hereinafter “Lease”]. 5 LA § 2.1.

4 (“KPI”);6 (ii) rules promulgated by the United States Food and Drug Administration

(“FDA”);7 and (iii) responsibilities listed in the “Operating Guidelines.”8

a. KPI #9

The KPI are bilaterally negotiated performance standards incorporated in the

Logistics Agreement that use task-specific metrics to determine whether the parties

are meeting each other’s expectations. One of them—KPI #9—is relevant here.

KPI #9 is directed to product damage.9 It imposes liability for “any [product

damage] claim arising out of . . . poor handling while on CuraScript’s premises.”10

In contrast to other provisions in the Logistics Agreement, KPI #9 is not tied to a

standard of care.11

The parties were contractually required to carry insurance coverage to

mitigate any liability for product damage. KPI #9 requires the parties to carry

insurance at a policy cap greater than the products’ “total value” or “replacement

cost.”12 But the Logistics Agreement does not contain language barring an insurer

from bringing a subrogation claim to recoup its payments for covered losses.

6 Id. § 2.5 (incorporating Ex. D to id. [hereinafter “KPI[#]”]). 7 Id. § 8. 8 Id. § 3.2 (incorporating Ex. A to id. [hereinafter “Operating Guidelines”]). 9 Id. § 2.1, 2.5; KPI #9. 10 KPI #9. 11 See, e.g., LA § 3.2 (articulating a “gross negligence or willful misconduct” standard); LA § 13 (articulating a “negligence” standard). 12 KPI #9.

5 b. Reg 211.208

The field of FDA regulation is vast. Unhelpfully, the Logistics Agreement

generally references FDA’s regulations, but does not identify any particular rule that

CuraScript must obey. The parties, however, agree that FDA’s “drug product

salvaging” rule (“Reg 211.208”) is the applicable rule.13 So the Court starts there.

Reg 211.208 is part of FDA’s “good manufacturing practices” or “GMP.”14

It regulates the sale of “drug products” that have been “subjected to improper storage

conditions.”15 Improper storage conditions are defined to include “extreme”

exposures to chemical and environmental forces caused by “equipment failures.”16

Under Reg 211.208, improperly stored drug products must be discarded.17

This mandate is consistent with GMP. FDA regulations provide that any “failure to

comply with” GMP “in the manufacture, processing, packing, or holding of a drug

shall render such drug . . . adulterated[.]”18 In other words, a drug product that

13 Drug Product Salvaging, 21 C.F.R. §

Related

Eli Lilly & Co. v. Air Express International USA, Inc.
615 F.3d 1305 (Eleventh Circuit, 2010)
Aspen Advisors LLC v. United Artists Theatre Co.
843 A.2d 697 (Court of Chancery of Delaware, 2004)
Lorillard Tobacco Co. v. American Legacy Foundation
903 A.2d 728 (Supreme Court of Delaware, 2006)
United States v. Richlyn Laboratories, Inc.
827 F. Supp. 1145 (E.D. Pennsylvania, 1992)
Beattie v. Beattie
786 A.2d 549 (Superior Court of Delaware, 2001)
Duphily v. Delaware Electric Cooperative, Inc.
662 A.2d 821 (Supreme Court of Delaware, 1995)
Brzoska v. Olson
668 A.2d 1355 (Supreme Court of Delaware, 1995)
Lee Tire & Rubber Co. of the State of NY v. Dormer
108 A.2d 168 (Supreme Court of Delaware, 1954)
Wal-Mart Stores, Inc. v. AIG Life Insurance
872 A.2d 611 (Court of Chancery of Delaware, 2005)
Insituform of North America, Inc. v. Chandler
534 A.2d 257 (Court of Chancery of Delaware, 1987)
Paul v. Deloitte & Touche, LLP
974 A.2d 140 (Supreme Court of Delaware, 2009)
Ward v. Shoney's, Inc.
817 A.2d 799 (Supreme Court of Delaware, 2003)
Rochester v. Katalan
320 A.2d 704 (Supreme Court of Delaware, 1974)
J.S. Alberici Construction Co. v. Mid-West Conveyor Co.
750 A.2d 518 (Supreme Court of Delaware, 2000)
City Investing Co. Liquidating Trust v. Continental Casualty Co.
624 A.2d 1191 (Supreme Court of Delaware, 1993)
Ebersole v. Lowengrub
180 A.2d 467 (Supreme Court of Delaware, 1962)
Triple C Railcar Service, Inc. v. City of Wilmington
630 A.2d 629 (Supreme Court of Delaware, 1993)
Phillips v. Delaware Power & Light Company
216 A.2d 281 (Supreme Court of Delaware, 1966)
United Vanguard Fund, Inc. v. TakeCare, Inc.
693 A.2d 1076 (Supreme Court of Delaware, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
Torrent Pharma, Inc. v. Priority Healthcare Distribution, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/torrent-pharma-inc-v-priority-healthcare-distribution-inc-delsuperct-2022.